Effective connectivity changes in LSD-induced altered states of consciousness in humans
In a double-blind, placebo-controlled cross-over study using spectral dynamic causal modelling of resting-state fMRI, the authors show that LSD alters effective connectivity within cortico–striato–thalamo–cortical circuits by increasing thalamus→posterior cingulate connectivity via serotonin 2A (5‑HT2A) receptor activation and decreasing ventral striatum→thalamus connectivity independently of 5‑HT2A. These results support the thalamic filter model of psychedelic action and advance mechanistic understanding relevant to therapeutic development.
Authors
- Franz Vollenweider
- Katrin Preller
- Philipp Stämpfli
Published
Abstract
Psychedelics exert unique effects on human consciousness. The thalamic filter model suggests that core effects of psychedelics may result from gating deficits, based on a disintegration of information processing within cortico–striato–thalamo-cortical (CSTC) feedback loops. To test this hypothesis, we characterized changes in directed (effective) connectivity between selected CTSC regions after acute administration of lysergic acid diethylamide (LSD), and after pretreatment with Ketanserin (a selective serotonin 2A receptor antagonist) plus LSD in a double-blind, randomized, placebo-controlled, cross-over study in 25 healthy participants. We used spectral dynamic causal modeling (DCM) for resting-state fMRI data. Fully connected DCM models were specified for each treatment condition to investigate the connectivity between the following areas: thalamus, ventral striatum, posterior cingulate cortex, and temporal cortex. Our results confirm major predictions proposed in the CSTC model and provide evidence that LSD alters effective connectivity within CSTC pathways that have been implicated in the gating of sensory and sensorimotor information to the cortex. In particular, LSD increased effective connectivity from the thalamus to the posterior cingulate cortex in a way that depended on serotonin 2A receptor activation, and decreased effective connectivity from the ventral striatum to the thalamus independently of serotonin 2A receptor activation. Together, these results advance our mechanistic understanding of the action of psychedelics in health and disease. This is important for the development of new pharmacological therapeutics and also increases our understanding of the mechanisms underlying the potential clinical efficacy of psychedelics.
Research Summary of 'Effective connectivity changes in LSD-induced altered states of consciousness in humans'
Introduction
Classic psychedelics produce profound alterations in mood, perception, cognition, and the sense of self, yet the neural mechanisms that give rise to these altered states remain incompletely understood. One influential account, the cortico‑striato‑thalamo‑cortical (CSTC) or thalamic‑filter model, proposes that psychedelics disrupt the thalamus’s capacity to gate sensory and sensorimotor information to the cortex, producing ‘‘sensory flooding’’ and cognitive disintegration. Neurotransmitter systems implicated in this model include serotonergic (notably 5‑HT2A), dopaminergic and glutamatergic pathways, but direct tests of the model’s predictions in humans have been lacking. Preller and colleagues set out to test the CSTC gating hypothesis by characterising directed (effective) connectivity among key CSTC nodes after acute administration of lysergic acid diethylamide (LSD), and after pretreatment with the selective 5‑HT2A antagonist ketanserin (Ket). Using spectral dynamic causal modelling (DCM) applied to resting‑state fMRI in a double‑blind, randomised, placebo‑controlled, crossover sample of healthy participants, the study tested two primary predictions: LSD would increase thalamus→cortex effective connectivity and reduce striatal (ventral striatum, VS) influence on the thalamus, and many of these LSD effects would depend on 5‑HT2A receptor stimulation.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019). Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proceedings of the National Academy of Sciences, 116(7), 2743-2748. https://doi.org/10.1073/pnas.1815129116
References (24)
Papers cited by this study that are also in Blossom
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)
Geyer, M. A., Vollenweider, F. X. · Trends in Pharmacological Sciences (2008)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)
Vollenweider, F. X., Csomor, P. A., Knappe, B. et al. · Neuropsychopharmacology (2007)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Show all 24 referencesShow fewer
Preller, K. H., Schilbach, L., Pokorny, T. et al. · Journal of Neuroscience (2018)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)
Kometer, M., Pokorny, T., Seifritz, E. et al. · Psychopharmacology (2015)
Preller, K. H., Pokorny, D., Hock, A. et al. · PNAS (2016)
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Pokorny, T., Preller, K. H., Kometer, M. et al. · International Journal of Neuropsychopharmacology (2017)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Lewis, C. R., Preller, K. H., Kraehenmann, R. et al. · NeuroImage (2017)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Cited By (69)
Papers in Blossom that reference this study
Girn, M., Doss, M. K., Roseman, L. et al. · Nature Medicine (2026)
Stoliker, D., Novelli, L., Khajehnejad, M. et al. · Biorxiv (2025)
Safron, A., Juliani, A., Reggente, N. et al. · Neuroscience of Consciousness (2025)
Caspani, G., Ruffell, S. G. D., Tsang, WF. et al. · Pharmacological Research (2024)
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · Biological Psychiatry (2024)
Bagdasarian, F. A., Hansen, H. D., Chen, J. et al. · ACS Chemical Neuroscience (2024)
Stoliker, D., Preller, K. H., Novelli, L. et al. · Molecular Psychiatry (2024)
Avram, M., Müller, F., Preller, K. H. et al. · Biological Psychiatry (2024)
Shinozuka, K., Tewarie, P. K. B., Luppi, A. et al. · Biorxiv (2024)
Lewis, E. C., Jaeger, A., Girn, M. et al. · Journal of Psychopharmacology (2024)
Show all 69 papersShow fewer
Tipado, Z., Kuypers, K. P. C., Sorger, B. et al. · European Neuropsychopharmacology (2024)
Murray, C., Frohlich, J, Haggarty, C. J., Tare, I. et al. · Neuropsychopharmacology (2024)
Pizzi, S. D., Chiacchiaretta, P., Sestieri, C. et al. · NeuroImage (2023)
Buchborn, T., Kettner, H., Kartner, L. et al. · Frontiers in Neuroscience (2023)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · Frontiers in Neuroscience (2023)
Wallach, J., Cao, A. B., Calkins, M. M. et al. · Biorxiv (2023)
Winkelman, M. J., Szabo, A., Frecska, E. · European Neuropsychopharmacology (2023)
Pizzi, S. D., Chiacchiaretta, P., Sestieri, C. et al. · Biological Psychiatry (2023)
Adamska, I., Finc, K. · Psychopharmacology (2023)
Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Humanistic Psychology (2023)
Ort, A., Smallridge, J. W., Sarasso, S. et al. · iScience (2023)
Sadibolova, R., Murray-Lawson, C., Family, N. et al. · Biorxiv (2023)
Ruffini, G., Damiani, G., Lozano-Soldevilla, D. et al. · PLOS ONE (2023)
Olsen, A. S., Ozenne, B., Madsen, M. K. et al. · NeuroImage (2022)
Bedford, P., Hauke, D. J., Wang, Z. et al. · Neuropsychopharmacology (2022)
Glazer', J., Murray, C. H., Nusslock', R. et al. · Neuropsychopharmacology (2022)
Kwan, A. C., Olson, D. E., Preller, K. H. et al. · Nature Medicine (2022)
Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Psychopharmacology (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Császár, N., Bob, P., Bókkon, I. · Journal of Integrative Neuroscience (2022)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Luppi, A. I., Hansen, J. Y., Adapa, R. et al. · Biorxiv (2022)
Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Aharon-Almagor, A., Barrett, F. S. · Research Square (2022)
Lawn, T., Dipasquale, O., Vamvakas, A. et al. · Psychopharmacology (2022)
Ciauncia, A., Safron, A. · Psyarxiv (2022)
Family, N., Hendricks, P. S., Williams, L. T. J. et al. · Journal of Psychopharmacology (2022)
Gaddis, A., Lidstone, D. E., Nebel, M. B. et al. · Biorxiv (2022)
Markopoulos, A., Inserra, A., De Gregorio, D. et al. · Frontiers in Pharmacology (2022)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · MedRvix (2021)
Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)
Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)
Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)
Avram, M., Rogg, H., Korda, A. et al. · Frontiers in Psychiatry (2021)
Perry, C. M., Malina, M. · Psychopharmacology (2021)
Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)
Zamani, A., Carhart-Harris, R. L., Christoff, K. · Neuropsychopharmacology (2021)
Rodriguiz, R. M., Nadkarni, V., Means, C. R. et al. · Scientific Reports (2021)
Domenico, C., Haggerty, D., Mou, X. et al. · Cell Reports (2021)
Burt, J. B., Preller, K. H., Demirtaş, M. et al. · eLife (2021)
Duerler, P., Brem, S., Fraga-González, G. et al. · Cerebral Cortex (2021)
Savino, A., Nichols, C. D. · Biorxiv (2021)
Bement, W., Banks, M. I., Zahid, Z. et al. · Molecular Biology of the Cell (2021)
Yaden, D. B., Johnson, M. W., Griffiths, R. R. et al. · International Journal of Neuropsychopharmacology (2021)
Jobst, B. M., Atasoy, S., Ponce-Alvarez, A. et al. · NeuroImage (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Hibicke, M., Gobbi, G. · Journal of Neuroscience (2020)
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)
Girn, M., Roseman, L., Bernhardt, B. et al. · Biorxiv (2020)
Bershad, A. K., Preller, K. H., Lee, R. et al. · Biological Psychiatry (2020)
Agin-Liebes, G. I., Malone, T., Yalch, M. M. et al. · Journal of Psychopharmacology (2020)
Ho, J. T., Preller, K. H., Lenggenhager, B. · Neuroscience and Biobehavioral Reviews (2020)
Family, N., Maillet, E. L., Williams, L. T. J. et al. · Psychopharmacology (2019)
Felix, M., Stefan, B. · Swiss Medical Weekly (2019)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.